Press Releases

BioIVT to Host Webinar on How to Evaluate BSEP Inhibition and Reduce Drug-induced Liver Injury (DILI) Risk during Drug Development

By Lauren Vagnone | July 10, 2019

DILI is a leading cause of drug development failures and a frequent cause of drug label restrictions

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a webinar that will present the latest in vitro research methods and International Transporter Consortium (ITC) guidance for assessing bile salt export pump (BSEP) inhibition to reduce and manage the risk of drug-induced liver injury (DILI) during drug development.
Read more

BioIVT HEPATOPAC® Meeting to Highlight Advances in Drug Discovery Research

By Lauren Vagnone | June 3, 2019

HEPATOPAC micropatterned hepatocyte cultures are optimized for drug safety, metabolism and efficacy research

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be hosting a HEPATOPAC Meeting at the AC Hotel by Marriott, San Francisco Airport/Oyster Point Waterfront on June 7. Presentations will show how the HEPATOPAC system can be employed in lead selection programs to investigate new drug candidates’ ADME-Tox profiles and assess their efficacy.
Read more

BioIVT Named Service Provider for Promega Immunotherapy Bioassays

By Lauren Vagnone | May 29, 2019

Demonstrating continuing support for immuno-oncology researchers, BioIVT extends excellence in research to help researchers screen novel therapeutics

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will now offer Promega Immune Checkpoint and antibody-dependent cell-mediated cytotoxicity (ADCC) Reporter Bioassays to support immunology and immuno-oncology research. This offering complements BioIVT’s custom assay development services using client-provided cells and reagents.Read more

New BioIVT Research on Botanical-Drug Interactions Published in Applied In Vitro Toxicology

By Lauren Vagnone | May 2, 2019

New BioIVT Research on Botanical-Drug Interactions Published in Applied In Vitro Toxicology

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that its ADME-Tox team has co-authored a second peer-reviewed paper investigating the potential for clinically-relevant botanical-drug interactions (BDIs) with toxicology colleagues at The Procter & Gamble Company (P&G).1 The paper describes a research collaboration by BioIVT and P&G based on studies conducted in BioIVT’s laboratory in Durham, NC.Read more

BioIVT Joins the Foundation for the National Institutes of Health Biomarkers Consortium

By Lauren Vagnone | March 25, 2019

BioIVT Joins the Foundation for the National Institutes of Health Biomarkers Consortium

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium.Read more

BioIVT Webinar to Discuss Ethical and Regulatory Issues Regarding Use of Human Biospecimens in Life Sciences Research in the UK and EU

By Lauren Vagnone | March 18, 2019

Ethical and Regulatory Issues Regarding Use of Human Biospecimens in Life Sciences Research in the UK and EU

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be co-hosting a one-hour webinar entitled “Gaining Clarity: Unique Considerations for the Ethical and Regulatory Use of Human Biospecimens in the European Union (EU) and United Kingdom (UK)” at 8 a.m. EST on Mar. 19.
Read more

BioIVT Launches Its XPRESSWAY® Profile Safety Package, a Gene Expression Reference Guide Designed to Improve Drug Safety Analyses

By Lauren Vagnone | March 6, 2019

BioIVT Launches Its XPRESSWAY® Profile Safety Package, a Gene Expression Reference Guide Designed to Improve Drug Safety Analyses

This new product will help pharmaceutical companies to assess drug safety risks, inform go/no-go decisions in lead selection, and expedite drug discovery programs.
Read more

BioIVT Acquires Biological Specialty Corporation, Adds Donor Centers and Increases Its Immune Cell Capacity

By Lauren Vagnone | November 5, 2018

BioIVT Acquires Biological Specialty Corporation, Adds Donor Centers and Increases Its Immune Cell Capacity

Acquisition increases BioIVT’s supply of leukopaks, plasma, and sera, and enhances its ability to support the in vitro diagnostic market.

Read more

BioIVT Appoints Alan Findlater as Chief Commercial Officer

By Lauren Vagnone | October 25, 2018

BioIVT Appoints Alan Findlater as Chief Commercial Officer

BioIVT is expanding its global commercial capabilities in response to growing demand for its biospecimens and specialized research services.

Read more

BioIVT Introduces New Quality Management System to Maintain Highest Quality Biospecimens and Drug Development Research Services

By Lauren Vagnone | October 16, 2018

BioIVT Introduces New Quality Management System to Maintain Highest Quality Biospecimens and Drug Development Research Services

QMS, Master Control will help to ensure consistent document tracking and training across all BioIVT sites and support the company’s rapid growth

Read more